148 related articles for article (PubMed ID: 20706125)
41. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
42. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
[TBL] [Abstract][Full Text] [Related]
43. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
[TBL] [Abstract][Full Text] [Related]
44. Duloxetine: a review of its pharmacology and use in chronic pain management.
Bellingham GA; Peng PW
Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
[TBL] [Abstract][Full Text] [Related]
45. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
[TBL] [Abstract][Full Text] [Related]
46. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Cui Z; Faries DE; Shen W; Able SL; Novick D
J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
[TBL] [Abstract][Full Text] [Related]
47. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
48. Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed?
Adhikari K; Patten SB; Lee S; Metcalfe A
Can J Psychiatry; 2019 Mar; 64(3):199-208. PubMed ID: 30252505
[TBL] [Abstract][Full Text] [Related]
49. Is there a place for duloxetine?
Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
[TBL] [Abstract][Full Text] [Related]
50. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
51. Effects of duloxetine on painful physical symptoms associated with depression.
Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
[TBL] [Abstract][Full Text] [Related]
52. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Westanmo AD; Gayken J; Haight R
Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
[TBL] [Abstract][Full Text] [Related]
53. Attributes of response in depressed patients switched to treatment with duloxetine.
Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
[TBL] [Abstract][Full Text] [Related]
54. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
55. Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
Ramos MG; Hara C; Rocha FL
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):579-80. PubMed ID: 17897763
[No Abstract] [Full Text] [Related]
56. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
57. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
58. Predictors of duloxetine adherence and persistence in patients with fibromyalgia.
Cui Z; Zhao Y; Novick D; Faries D
J Pain Res; 2012; 5():193-201. PubMed ID: 22792005
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study.
Chen S; Wu N; Boulanger L; Fraser K; Zhao Z; Zhao Y
J Med Econ; 2011; 14(4):411-20. PubMed ID: 21615268
[TBL] [Abstract][Full Text] [Related]
60. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.
Wohlreich MM; Mallinckrodt CH; Watkin JG; Wilson MG; Greist JH; Delgado PL; Fava M
Ann Clin Psychiatry; 2005; 17(4):259-68. PubMed ID: 16402760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
